PFIZER INC
PFELatest QuantConomy context for PFE: asset profile, market coverage, scored signals, and source-linked SEC insider filings when available.
PFIZER INC
Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered in Manhattan, New York City. Established in 1849 by Charles Pfizer and his cousin, the company develops, manufactures, markets, and distributes a wide range of biopharmaceutical products globally. Pfizer's product portfolio includes medicines and vaccines for various therapeutic areas such as immunology, oncology, cardiology, endocrinology, and neurology. Key products include the Pfizer-BioNTech COVID-19 vaccine, the pneumococcal conjugate vaccine Prevnar 13, and treatments like Eliquis and Ibrance. The company operates internationally, with a significant portion of its revenues coming from outside the United States, and employs approximately 88,000 people worldwide. Pfizer is one of the largest pharmaceutical companies globally, known for its extensive research and development efforts and its commitment to innovation in healthcare.
- Symbol
- PFE
- Name
- PFIZER INC
- Coverage
- 3 market/data records
- Sources
- alphavantage fmp alpaca sec axs nasdaq
Recent signals for PFE
Scored rows are pulled from the same signal API used by the digests.
| Signal | Direction | Score | Observed | Reason |
|---|---|---|---|---|
| major spike | neutral | 54 | Jul 10, 07:59 PM | PFE major volume spike: 506% of expected volume for Friday 19:00 UTC, price flat 0.27% (strength 54) |
| sustained dry up | neutral | 53 | Jul 10, 06:01 PM | PFE sustained volume dry-up: 13% of expected volume for Friday 18:00 UTC, price flat 0.10% (strength 53) |
| dry up | neutral | 61 | Jul 10, 05:06 PM | PFE volume dry-up: 4% of expected volume for Friday 17:00 UTC, price flat 0.06% (strength 61) |
EARNINGS signals are experimental: currently limited to neutral pre-earnings calendar awareness (no transcript analysis).
Market coverage
| Market | Exchange | Source | Asset record |
|---|---|---|---|
| PFE | NYSE | alphavantage | Pfizer Inc |
| PFE | NYSE | fmp | Pfizer Inc. |
| PFE | NYSE | alpaca | Pfizer Inc. |
Recent insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Jun 30, 2026 | BOURLA ALBERT | Chairman & CEO | grant | 25 | $24.08 | $602 | 4 on EDGAR |
| Jun 26, 2026 | Quincey James | Insider | grant | 1,595 | $24.29 | $38,750 | 4 on EDGAR |
| Jun 26, 2026 | NARAYEN SHANTANU | Insider | grant | 2,058 | $24.29 | $50,000 | 4 on EDGAR |
| Jun 26, 2026 | Buckley Mortimer J | Insider | grant | 1,544 | $24.29 | $37,500 | 4 on EDGAR |
| Jun 26, 2026 | Taraporevala Cyrus | Insider | grant | 1,544 | $24.29 | $37,500 | 4 on EDGAR |
| Jun 26, 2026 | Echevarria Joseph | Insider | grant | 1,904 | $24.29 | $46,250 | 4 on EDGAR |
| Jun 15, 2026 | BOURLA ALBERT | Chairman & CEO | grant | 23 | $26.00 | $598 | 4 on EDGAR |
| Jun 9, 2026 | DAMICO JENNIFER B. | SVP & Controller | sale | 2,000 | $25.70 | $51,400 | 4 on EDGAR |
| May 29, 2026 | BOURLA ALBERT | Chairman & CEO | grant | 23 | $26.18 | $602 | 4 on EDGAR |
| May 15, 2026 | BOURLA ALBERT | Chairman & CEO | grant | 24 | $25.33 | $608 | 4 on EDGAR |
| Apr 30, 2026 | BOURLA ALBERT | Chairman & CEO | grant | 22 | $26.70 | $587 | 4 on EDGAR |
| Apr 23, 2026 | Taraporevala Cyrus | Insider | grant | 7,687 | $26.67 | $205,000 | 4 on EDGAR |
| Apr 23, 2026 | LITTMAN DAN R. | Insider | grant | 7,687 | $26.67 | $205,000 | 4 on EDGAR |
| Apr 23, 2026 | Echevarria Joseph | Insider | grant | 7,687 | $26.67 | $205,000 | 4 on EDGAR |
| Apr 23, 2026 | Desmond-Hellmann Susan | Insider | grant | 7,687 | $26.67 | $205,000 | 4 on EDGAR |
| Apr 23, 2026 | NORA JOHNSON SUZANNE M | Insider | grant | 7,687 | $26.67 | $205,000 | 4 on EDGAR |
| Apr 23, 2026 | Quincey James | Insider | grant | 7,687 | $26.67 | $205,000 | 4 on EDGAR |
| Apr 23, 2026 | NARAYEN SHANTANU | Insider | grant | 7,687 | $26.67 | $205,000 | 4 on EDGAR |
| Apr 23, 2026 | Gottlieb Scott | Insider | grant | 7,687 | $26.67 | $205,000 | 4 on EDGAR |
| Apr 23, 2026 | SMITH JAMES C | Insider | grant | 7,687 | $26.67 | $205,000 | 4 on EDGAR |
Source: SEC filings via QuantConomy. Not investment advice.
Query PFE context like a database.
These rows come from the QuantConomy signal, asset, market, and SEC filings API surfaces, also available to AI agents over MCP.
More: All insider trades · How to read a Form 4 · API access